U.S. Markets close in 2 hrs 32 mins

MediWound Ltd. (MDWD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.9800+0.2200 (+5.85%)
As of 1:24PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.7600
Bid3.9800 x 1100
Ask4.0000 x 2200
Day's Range3.7800 - 4.0750
52 Week Range1.4430 - 4.4400
Avg. Volume175,748
Market Cap108.3M
Beta (5Y Monthly)1.52
PE Ratio (TTM)16.38
EPS (TTM)0.2430
Earnings DateAug 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.30
  • MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020

    YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 at 7:00 am Eastern Time on Thursday, August 6, 2020. Following the release, MediWound's management will host a conference call and live webcast on Thursday, August 6, 2020 at 8:30 am Eastern Time to discuss the financial results and to answer questions. Dial-in and call details are as follows:Conference Call & Webcast Details  Toll-Free:877-602-7189 Israel Toll-Free:1 809 315 362 International:678-894-3057 Conference ID:3176168 Webcast:https://edge.media-server.com/mmc/p/jt3zx63y To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.  An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.About MediWound Ltd. MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue. The product has received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health. MediWound’s second innovative product, EscharEx® is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid.  In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.  For more information, please visit www.mediwound.com.Contacts:  Boaz Gur-Lavie Jeremy Feffer Chief Financial OfficerManaging Director MediWound Ltd.LifeSci Advisors, LLC ir@mediwound.com jeremy@LifeSciAdvisors.com